Vivos Therapeutics, Inc. (VVOS): Entry into a Material Definitive Agreement

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test Transaction Expected to Increase Stockholders’ Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances LITTLETON, Colo., Oc

Event · M&A · definitive agreement
Role
acquirer
Counterparty
SOD Sciences
Deal value
$12 million
Consideration
stock
Expected close
on or about October 15, 2026

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 15, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$VVOS
Neutral
high confidence
Mentioned
$VVOS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VVOSNeutralMed
01

Why it matters

The deal aims to boost stockholders' equity to meet Nasdaq listing standards and create a new high‑margin revenue line through the ReBalU test, but execution risk remains.

02

Market read

The announcement may move VVOS modestly as investors assess compliance benefits versus dilution, with limited spillover to the broader sleep‑medicine sector.

03

What to watch

Regulatory clearance for the pseudohypoxia test and the timeline for commercial rollout may delay expected revenue.

Relevance 6/10Novelty 6/10Timing: today

Background

Vivos Therapeutics is a Nasdaq‑listed medical‑device company focused on obstructive sleep apnea treatments. The 8‑K filing details a strategic partnership with SOD Sciences.

Company-level read

Ticker impact

$VVOSNeutralHigh confidence
Context

Vivos Therapeutics filed an 8‑K announcing a definitive agreement to acquire an 11% stake in SOD Sciences and a 50% interest in its pseudohypoxia test, issuing $12 M of Series C convertible preferred stock.

Expected impact

modest upside pressure as investors price in compliance support, offset by dilution concerns

Evidence & confidence

The deal is material for a micro‑cap, introduces new assets and potential revenue, yet the $12 M equity raise is modest relative to market cap.

Market effects

Adds a new diagnostic test to the sleep‑apnea device sector, potentially raising competitive pressure on existing CPAP manufacturers.

Primarily U.S. market impact as Vivos is Nasdaq‑listed; limited effect on broader markets.

Low global relevance beyond niche sleep‑medicine investors.

Counterpoint

The preferred‑stock issuance could trigger short‑term selling pressure if dilution outweighs compliance benefits.

Key entities

  • Vivos Therapeutics, Inc.

    Nasdaq‑listed developer of sleep‑apnea devices.

  • SOD Sciences, Inc.

    Owner of the proprietary pseudohypoxia early‑warning test.

Related articles

$VVOSHigh

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

$VVOSHigh

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

$SPGIMed

S&P Global prices $2 billion senior notes offering

S&P Global (SPGI) priced a $2 billion senior notes offering in three tranches, with yields ranging from 5.635% to 6.001%. The notes are due 2031, 2034, and 2036, and proceeds will be used for general corporate purposes. The offering is expected to close around November 18, 2026, and is managed by several major financial institutions. The notes will be unsecured obligations of the company, guaranteed by a subsidiary.